Cytogen Corporation (CYTO) Reports Updated Data From a Phase 1 Dose Escalation Study Evaluating QUADRAMET
Cytogen Corporation (NASDAQ: CYTO) reported updated data from a Phase 1 dose escalation study evaluating QUADRAMET(R) (samarium Sm-153 lexidronam injection) in combination with bortezomib (Velcade(R), Millennium Pharmaceuticals, Inc.) in patients with relapsed multiple myeloma. Data from 33 patients were presented today in a poster titled, "Phase 1 Trial of Bortezomib (Vel) and Samarium (Sam) in Multiple Myeloma," by James Berenson, M.D., Medical & Scientific Director of the Institute for Myeloma & Bone Cancer Research in West Hollywood, California, at the XIth International Myeloma Workshop taking place in Greece.
You May Also Be Interested In
- Dow Chemical (DOW) Wins $2.16B in K-Dow Arbitration
- Chinese official has said Chinese banks may fall short of the 2012 lending goal -Bloomberg
- Mylan Inc. (MYL) Settles Patent Litigation with Sunovion Pharmaceuticals
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
